Pulse Biosciences (PLSE) Competitors

$24.55 0.00 (0.00%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$24.69 +0.14 (+0.59%)

As of 05/15/2026 07:44 PM Eastern

PLSE vs. LQDA, NVST, LIVN, IRTC, and MMED

Should you buy Pulse Biosciences stock or one of its competitors? MarketBeat compares Pulse Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulse Biosciences include Liquidia (LQDA), Envista (NVST), LivaNova (LIVN), iRhythm Technologies (IRTC), and MiniMed Group (MMED). These companies are all part of the "medical equipment" industry.

How does Pulse Biosciences compare to Liquidia?

Pulse Biosciences (NASDAQ:PLSE) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Pulse Biosciences currently has a consensus target price of $30.00, indicating a potential upside of 22.20%. Liquidia has a consensus target price of $49.33, indicating a potential downside of 13.34%. Given Pulse Biosciences' higher probable upside, equities analysts plainly believe Pulse Biosciences is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92

Pulse Biosciences has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Liquidia has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	4,854.59	-$72.78M	-$1.10	N/A
Liquidia	$158.32M	31.98	-$68.92M	$0.14	406.64

Liquidia has a net margin of 7.74% compared to Pulse Biosciences' net margin of 0.00%. Liquidia's return on equity of 46.82% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Liquidia	7.74%	46.82%	7.06%

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Liquidia had 45 more articles in the media than Pulse Biosciences. MarketBeat recorded 55 mentions for Liquidia and 10 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.84 beat Liquidia's score of 0.61 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	17 Very Positive mention(s)	9 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Liquidia beats Pulse Biosciences on 11 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Envista?

Pulse Biosciences (NASDAQ:PLSE) and Envista (NYSE:NVST) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

In the previous week, Pulse Biosciences had 4 more articles in the media than Envista. MarketBeat recorded 10 mentions for Pulse Biosciences and 6 mentions for Envista. Pulse Biosciences' average media sentiment score of 0.84 beat Envista's score of 0.54 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Envista	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 1.0% of Envista shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulse Biosciences has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Envista has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Pulse Biosciences currently has a consensus target price of $30.00, indicating a potential upside of 22.20%. Envista has a consensus target price of $28.83, indicating a potential upside of 24.09%. Given Envista's stronger consensus rating and higher probable upside, analysts plainly believe Envista is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Envista has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	4,854.59	-$72.78M	-$1.10	N/A
Envista	$2.72B	1.39	$47M	$0.41	56.67

Envista has a net margin of 2.41% compared to Pulse Biosciences' net margin of 0.00%. Envista's return on equity of 7.11% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Envista	2.41%	7.11%	3.91%

Summary

Envista beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to LivaNova?

Pulse Biosciences (NASDAQ:PLSE) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

In the previous week, Pulse Biosciences had 7 more articles in the media than LivaNova. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for LivaNova. LivaNova's average media sentiment score of 0.98 beat Pulse Biosciences' score of 0.84 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Pulse Biosciences currently has a consensus target price of $30.00, indicating a potential upside of 22.20%. LivaNova has a consensus target price of $77.22, indicating a potential upside of 10.32%. Given Pulse Biosciences' higher possible upside, research analysts plainly believe Pulse Biosciences is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Pulse Biosciences has higher earnings, but lower revenue than LivaNova. Pulse Biosciences is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	4,854.59	-$72.78M	-$1.10	N/A
LivaNova	$1.39B	2.77	-$242.47M	$1.95	35.90

LivaNova has a net margin of 7.48% compared to Pulse Biosciences' net margin of 0.00%. LivaNova's return on equity of 16.48% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
LivaNova	7.48%	16.48%	7.59%

Summary

LivaNova beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to iRhythm Technologies?

Pulse Biosciences (NASDAQ:PLSE) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

iRhythm Technologies has higher revenue and earnings than Pulse Biosciences. iRhythm Technologies is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	4,854.59	-$72.78M	-$1.10	N/A
iRhythm Technologies	$747.14M	5.01	-$44.55M	-$0.86	N/A

Pulse Biosciences currently has a consensus target price of $30.00, indicating a potential upside of 22.20%. iRhythm Technologies has a consensus target price of $193.38, indicating a potential upside of 69.64%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pulse Biosciences has a net margin of 0.00% compared to iRhythm Technologies' net margin of -3.53%. iRhythm Technologies' return on equity of -10.26% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

In the previous week, Pulse Biosciences had 4 more articles in the media than iRhythm Technologies. MarketBeat recorded 10 mentions for Pulse Biosciences and 6 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.37 beat Pulse Biosciences' score of 0.84 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRhythm Technologies beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Pulse Biosciences (NASDAQ:PLSE) are both medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

MiniMed Group has higher revenue and earnings than Pulse Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.01	N/A	N/A	N/A
Pulse Biosciences	$350K	4,854.59	-$72.78M	-$1.10	N/A

MiniMed Group presently has a consensus target price of $22.25, indicating a potential upside of 106.02%. Pulse Biosciences has a consensus target price of $30.00, indicating a potential upside of 22.20%. Given MiniMed Group's stronger consensus rating and higher possible upside, equities analysts plainly believe MiniMed Group is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

19.7% of MiniMed Group shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MiniMed Group's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Pulse Biosciences	N/A	-86.67%	-73.61%

In the previous week, Pulse Biosciences had 6 more articles in the media than MiniMed Group. MarketBeat recorded 10 mentions for Pulse Biosciences and 4 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 1.37 beat Pulse Biosciences' score of 0.84 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiniMed Group beats Pulse Biosciences on 8 of the 12 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.70B	$6.69B	$6.25B	$12.29B
Dividend Yield	N/A	1.76%	2.81%	5.30%
P/E Ratio	-22.32	49.11	20.63	25.26
Price / Sales	4,854.59	68.87	555.02	73.57
Price / Cash	N/A	24.43	27.48	37.27
Price / Book	20.63	6.45	9.80	6.71
Net Income	-$72.78M	$158.81M	$3.57B	$336.00M
7 Day Performance	28.67%	-2.05%	-1.04%	-0.68%
1 Month Performance	4.91%	-6.28%	-2.62%	-0.06%
1 Year Performance	42.82%	-4.45%	33.54%	30.62%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	2.5079 of 5 stars	$24.55 flat	$30.00 +22.2%	+42.8%	$1.70B	$350K	N/A	140	Gap Up
LQDA Liquidia	2.8641 of 5 stars	$56.60 +6.5%	$49.33 -12.8%	+201.5%	$4.72B	$158.32M	404.31	50	Trending News Earnings Report Analyst Upgrade Insider Trade High Trading Volume
NVST Envista	3.6322 of 5 stars	$24.29 +0.4%	$28.83 +18.7%	+27.4%	$3.94B	$2.72B	59.24	12,000	Gap Up
LIVN LivaNova	2.5263 of 5 stars	$71.75 +2.4%	$77.22 +7.6%	+57.7%	$3.85B	$1.39B	36.79	3,300
IRTC iRhythm Technologies	4.4641 of 5 stars	$118.31 +1.3%	$193.38 +63.5%	-19.1%	$3.84B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, NVST, LIVN, IRTC, and MMED

How does Pulse Biosciences compare to Liquidia?

Summary

How does Pulse Biosciences compare to Envista?

Summary

How does Pulse Biosciences compare to LivaNova?

Summary

How does Pulse Biosciences compare to iRhythm Technologies?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. LQDA, NVST, LIVN, IRTC, and MMED

How does Pulse Biosciences compare to Liquidia?

Do analysts rate PLSE or LQDA?

Which has more volatility and risk, PLSE or LQDA?

Which has stronger valuation and earnings, PLSE or LQDA?

Is PLSE or LQDA more profitable?

Do insiders and institutionals believe in PLSE or LQDA?

Does the media refer more to PLSE or LQDA?

Summary

How does Pulse Biosciences compare to Envista?

Does the media refer more to PLSE or NVST?

Do insiders and institutionals believe in PLSE or NVST?

Which has more volatility and risk, PLSE or NVST?

Do analysts rate PLSE or NVST?

Which has stronger valuation and earnings, PLSE or NVST?

Is PLSE or NVST more profitable?

Summary

How does Pulse Biosciences compare to LivaNova?

Does the media refer more to PLSE or LIVN?

Do institutionals and insiders believe in PLSE or LIVN?

Which has more risk and volatility, PLSE or LIVN?

Do analysts rate PLSE or LIVN?

Which has higher valuation & earnings, PLSE or LIVN?

Is PLSE or LIVN more profitable?

Summary

How does Pulse Biosciences compare to iRhythm Technologies?

Which has higher valuation & earnings, PLSE or IRTC?

Do analysts rate PLSE or IRTC?

Which has more risk and volatility, PLSE or IRTC?

Do institutionals and insiders believe in PLSE or IRTC?

Is PLSE or IRTC more profitable?

Does the media refer more to PLSE or IRTC?

Summary

How does Pulse Biosciences compare to MiniMed Group?

Which has higher earnings and valuation, MMED or PLSE?

Do analysts prefer MMED or PLSE?

Do insiders & institutionals have more ownership in MMED or PLSE?

Is MMED or PLSE more profitable?

Does the media refer more to MMED or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools